Aims-To investigate the expression pattern of Epstein-Barr virus (EBV) latent genes at the single cell level in posttransplantation lymphoproliferative disorders and acquired immunodefiency syndrome (AIDS) related lymphomas, in relation to cellular morphology. Methods-Nine post-transplantation lymphoproliferative disorders and three AIDS related lymphomas were subjected to immunohistochemistry using monoclonal antibodies specific for EBV nuclear antigen 1 (EBNA1) (2H4), EBNA2 (PE2 and the new rat anti-EBNA2 monoclonal antibodies 1E6, R3, and 3E9), and LMP1 (CS1-4 and S12). Double try in a subpopulation of tumour cells using sensitive monoclonal antibodies R3 and 3E9. Our data suggest that EBV infected tumour cells in these lymphomas undergo gradual changes in the expression of EBV latent genes, and that these changes are associated with changes in cellular morphology. (J Clin Pathol 1997;50:91 1-918) 
plastic cells coexpressing EBNA2 and LMP1 (EBV latency type III), were detected using R3 and 3E9, and formed a considerable part of the neoplastic population in four of nine post-transplantation lymphoproliferative disorders and two of three AIDS related lymphomas. All samples contained a subpopulation of small tumour cells positive exclusively for Epstein-Barr early RNA and EBNA1. The relation between cellular morphology and EBV expression patterns in this study was less pronounced in AIDS related lymphomas than in post-transplantation lymphoproliferative disorders, because the AIDS related lymphomas were less polymorphic than the post-transplantation lymphoproliferative disorders. Conclusions-In post-transplantation lymphoproliferative disorders and AIDS related lymphomas, EBV latency type III can be detected by immunohistochemistry in a subpopulation of tumour cells using sensitive monoclonal antibodies R3 and 3E9. Our data suggest that EBV infected tumour cells in these lymphomas undergo gradual changes in the expression of EBV latent genes, and that these changes are associated with changes in cellular morphology. EBV is also associated with lymphomas of immunocompromised patients,7 such as acquired immunodefiency syndrome (AIDS) related lymphomas and post-transplantation lymphoproliferative disorders. EBV is thought to contribute to malignant transformation in all of these these disorders. 3 In LCLs and EBV positive malignancies, the virus is present latently and is transcriptionally active. To date, 12 gene products have been detected in association with EBV latency. However, in EBV positive lymphomas in immunocompetent patients, usually the EBV gene expression pattern is restricted. A limited expression pattern termed latency type I8 is detected in Burkitt's lymphoma. This implies expression of the transcription factor EBV nuclear antigen 1 (EBNA1), the small non-coding RNAs EBER1 and 2, and the BARFO transcripts.9 In EBV positive Hodkin's disease and nasal T nonHodgkin's lymphomas in immunocompetent patients, the Epstein-Barr early RNAs Four cases of post-transplantation lymphoproliferative disorder were obtained from the department of pathology of the Academical Hospital, Leiden. Material from five posttransplantation lymphoproliferative disorders, three AIDS related lymphomas, and one infectious mononucleosis case was obtained from the Academical Hospital of Utrecht. Characteristics of these samples are summarised in table 1. The site of origin of these tumours was difficult to determine as most of them were generalised at the time of diagnosis. Instead, the site ofbiopsy is mentioned when known. To verify EBV association, EBER RNA in situ hybridisation was performed on 4 ,um paraffin sections as described previously.26 As a positive control for EBER RNA in situ hybridisation, an EBV positive case of Hodgkin's disease was used. Hybridisation of all samples with the EBER sense probe served as a negative control; moreover, the non-neoplastic infiltrate in the EBV positive Hodgkin's disease case was always negative using EBER RNA in situ hybridisation. Immunohistochemistry was also performed on 4 gm sections. 912 mer, Munich, Germany). R3 recognises epitopes specific for EBV type 1, 3E9 recognises EBV type 2 encoded EBNA2, and 1E6 recognises both.25 As a reference for sensitivity the anti-EBNA2 monoclonal antibody PE2 (Dako, Glostrup, Denmark) was used. As a reference for the specificity of these monoclonal antibodies for the two EBV types we compared immunohistochemistry with DNA PCR. For detection of LMP1, both mouse LMP1 anti-LMP1 monoclonal antibody S12 (Organon Teknika, Boxtel, Netherlands) and the mixture of four anti-LMP1 antibodies CS1-4 (Dako) were used. EBNA1 protein was detected using the 2B4 monoclonal antibody28
(kindly provided by Dr E Kremmer, Munich, Germany). Of the EBV positive lymphomas, eight posttransplantation lymphoproliferative disorders were shown to harbour EBV type 1 using DNA PCR with EBNA2 specific primers as described previously27 (one sample was not tested owing to lack of material). Two AIDS related lymphomas contained EBV type 1, and one AIDS related lymphoma contained EBV type 2. As shown by DNA PCR, the EBV positive cell lines harboured EBV type 1 with the exception ofJC5, which contained EBV type 2.
Furthermore, all lymphomas and EBV positive cell lines were shown to express EBNA1, EBNA2, and LMP1 at the mRNA level using RT-PCR as described previously,"4 with the exception of the HH514C16 cell line, which did not express EBNA2 owing to a genomic deletion.
MONOCLONAL ANTIBODIES
To enable efficient detection of low concentrations of EBNA2 protein, we used several highly sensitive anti-EBNA2 rat monoclonal antibodies, which have been developed recently (R3, 3E9, and 1E6, kindly provided by Dr E Krem- gives stronger signals and stains more cells positive than CS1-429; therefore, S12 was used Post-transplantation lymphoproliferative disorders In this disorder, numbers of EBNA2 positive cells varied from 5-90% of the neoplastic population using the R3 monoclonal. EBER1/2, EBNA1, and EBNA2 staining of successive slides revealed the presence, of a small population positive exclusively for EBER1/2 and EBNA1. EBNA1 was detected in both large and small neoplastic cells (fig 3) . None of the post-transplantation lymphoproliferative disorders stained positive with the 3E9 monoclonal antibody, which is specific for EBV type 2 encoded EBNA2. This was in agreement with DNA PCR results, which had revealed the presence of EBV type 1 but not type 2 in all of the post-transplantation lymphoproliferative disorder biopsies.
Using the S12 anti-LMP1 monoclonal antibody, LMP1 expression could be detected only in the cytoplasm and membranes of large blastic, sometimes Reed-Sternberg-like tumour cells ( fig 4B) . In smaller tumour cells, LMP1 was not detected. Six out of nine posttransplantation lymphoproliferative disorders, and the infectious mononucleosis case stained positive for LMP 1 (table 3) . 
AIDS related lymphomas
In two of the three AIDS related lymp 5-75% of the lymphoma cells were I positive using the R3 antibody (samples 12, 
